BRAF and neoplasm: Upon further stratification of data based on clinicopathologic and prognostic characteristics, survival curves for patients with low and high expression of BRAF were not significantly different according to tumor stage, grade, and molecular subtype (Figures 4(d), 4(e), 4(f), 4(g), 4(h), and 4(i)).